KERICURE INC. — Department of Defense SBIR Phase III: KERICURE, INC. DHA SBIR PHASE III CLINICAL VALIDATION OF A PORTABLE, RUGGEDIZED ANTIMICROB
KERICURE INC. — SBIR Phase III award from Department of Defense.
Phase III transition / production-path signal
- Phase III work is typically non-SBIR set-aside follow-on. Seeing KERICURE INC. at Phase III is a strong transition indicator in this domain.
- Competitors studying dual-use scale-up should treat Phase III firms as graduation benchmarks, not just Phase I/II volume leaders.
- At $3,111,212, this is a large obligation for typical SBIR Phase sizing — worth reviewing for scope breadth and teaming opportunity.
- Tagged technology areas: Human Performance & Medical. Follow those hubs for open topics and peer winners in the same cluster.
Summary
Kericure Inc. received over $3.1 million from the Defense Health Agency to clinically validate their portable, ruggedized antimicrobial wound dressing. This dressing helps manage large burn areas during prolonged field care and long-term treatment.
- Amount
- $3,111,212
- Agency
- Department of Defense · Defense Health Agency
- Program / Phase
- SBIR · Phase III
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- FL
- Period
- 2023-09-25 → 2027-01-24
Technology domains
Description
KERICURE, INC. DHA SBIR PHASE III CLINICAL VALIDATION OF A PORTABLE, RUGGEDIZED ANTIMICROBIAL WOUND DRESSING IN MANAGEMENT OF LARGE SURFACE AREA BURNS FOR PROLONGED FIELD CARE AND LONG-TERM CARE